Safety and Efficacy of the BNT162b2 mRNA Covid-19 Vaccine
Open accessThe DOI matches its Crossref record; 9 of the 9 references it cites were found in a registry or an index; 9 of the 13 sources its claims cite were checked for support.
Abstract
BACKGROUND: Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection and the resulting coronavirus disease 2019 (Covid-19) have afflicted tens of millions of people in a worldwide pandemic. Safe and effective vaccines are needed urgently. METHODS: In an ongoing multinational, placebo-controlled, observer-blinded, pivotal efficacy trial, we randomly assigned persons 16 years of age or older in a 1:1 ratio to receive two doses, 21 days apart, of either placebo or the BNT162b2 vaccine candidate (30 μg per dose). BNT162b2 is a lipid nanoparticle-formulated, nucleoside-modified RNA vaccine that encodes a prefusion stabilized, membrane-anchored SARS-CoV-2 full-length spike protein. The primary end points were efficacy of the vaccine against laboratory-confirmed Covid-19 and safety. RESULTS: A total of 43,548 participants underwent randomization, of whom 43,448 received injections: 21,720 with BNT162b2 and 21,728 with placebo. There were 8 cases of Covid-19 with onset at least 7 days after the second dose among participants assigned to receive BNT162b2 and 162 cases among those assigned to placebo; BNT162b2 was 95% effective in preventing Covid-19 (95% credible interval, 90.3 to 97.6). Similar vaccine efficacy (generally 90 to 100%) was observed across subgroups defined by age, sex, race, ethnicity, baseline body-mass index, and the presence of coexisting conditions. Among 10 cases of severe Covid-19 with onset after the first dose, 9 occurred in placebo recipients and 1 in a BNT162b2 recipient. The safety profile of BNT162b2 was characterized by short-term, mild-to-moderate pain at the injection site, fatigue, and headache. The incidence of serious adverse events was low and was similar in the vaccine and placebo groups. CONCLUSIONS: A two-dose regimen of BNT162b2 conferred 95% protection against Covid-19 in persons 16 years of age or older. Safety over a median of 2 months was similar to that of other viral vaccines. (Funded by BioNTech and Pfizer; ClinicalTrials.gov number, NCT04368728.).
Overview
CoChat Summary
TL;DR
In a phase 2/3 multinational trial, two 30-μg doses of BNT162b2 given 21 days apart were 95% effective against laboratory-confirmed Covid-19 in participants 16 years of age or older. The vaccine’s safety profile was characterized mainly by short-term, mild-to-moderate local and systemic reactions, with serious adverse events similar between vaccine and placebo groups.
Key findings
- Among 43,548 randomized participants, 43,448 received injections: 21,720 BNT162b2 and 21,728 placebo. In the efficacy population without prior infection, there were 8 Covid-19 cases in vaccine recipients vs. 162 in placebo recipients, corresponding to 95.0% vaccine efficacy (95% CI, 90.3 to 97.6).
- Among participants with or without evidence of prior SARS-CoV-2 infection, 9 Covid-19 cases occurred in vaccine recipients vs. 169 in placebo recipients, for 94.6% efficacy (95% CI, 89.9 to 97.3).
- Of 10 severe Covid-19 cases with onset after the first dose, 9 occurred in placebo recipients and 1 in a BNT162b2 recipient. Between the first and second doses, vaccine efficacy was 52% (95% CI, 29.5 to 68.4).
- Reactogenicity was mostly mild-to-moderate; common events included injection-site pain, fatigue, and headache. Serious adverse events occurred in 0.6% of vaccine recipients and 0.5% of placebo recipients.
Methods
- Ongoing multinational, placebo-controlled, observer-blinded, pivotal efficacy trial; participants 16 years of age or older were randomly assigned 1:1 to receive two doses, 21 days apart, of 30 μg BNT162b2 or saline placebo.
- Primary end points were efficacy against laboratory-confirmed Covid-19 and safety. Efficacy was estimated as 100×(1−IRR), with a Bayesian beta-binomial model; safety analyses were descriptive.
- The main safety subset included 37,706 participants with a median of at least 2 months of safety data after the second dose; the reactogenicity subset included 8,183 participants.
Limitations
- The paper states that with approximately 19,000 participants per group and a median follow-up of 2 months after the second dose, the trial is not large enough to detect less common adverse events reliably; longer-term adverse events and durability of protection remain to be determined.
- The paper states that ethical and practical barriers prevent following placebo recipients for the planned 2 years once the vaccine is approved and recommended, and that the data do not address whether vaccination prevents asymptomatic infection or establish a correlate of protection.
- The paper states that it does not address prevention of Covid-19 in younger adolescents, children, or pregnant women; the text also makes evident that the main safety subset was 49% female, 83% White, 9% Black or African American, 28% Hispanic or Latinx, with a median age of 52 years, which may limit generalizability.
Model-written summary. Check it against the paper before relying on it.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
6 Valid · 1 Not valid · 3 Not checked · 59 Own results and interpretations
The cited sources support only part of this claim — read each source’s verdict below.
In the paper
“The favorable safety profile observed during phase 1 testing of BNT162b24,8 was confirmed in the phase 2/3 portion of the trial.”
§ Safety and Efficacy of the BNT162b2 mRNA Covid-19 Vaccine > Discussion
What the sources say
- Partly supportedcites [4] Walsh EE, Frenck RW Jr, Falsey AR, et al. Safety and immunogenicity of two RNA-based Covid-19 vaccine candidates. N Engl J Med. DOI: 10.1056/NEJMoa2027906. PMC7583697 33053279 sourceExperimental — accuracy not yet measured
The Introduction reports safety data from the Phase 1 portion of the trial, and the Discussion says those data helped select BNT162b2 for Phase 2/3 evaluation. The Discussion describes Phase 2/3 safety assessment as ongoing; this paper does not report Phase 2/3 results confirming the Phase 1 safety profile. No page numbers are available in our copy. (LLM, conf=0.90)
- Partly supportedcites [8] Sahin U, Muik A, Vogler I, et al. BNT162b2 induces SARS-CoV-2-neutralising antibodies and T cells in humans. December 11, 2020 (https://www.medrxiv.org/content/10.1101/2020.12.09.20245175v1). preprint. sourceExperimental — accuracy not yet measured
The Safety and tolerability section reports no related serious adverse events, grade-4 reactions, or withdrawals due to related adverse events in this phase-I/II study, supporting the description of a favorable early safety profile. The paper does not report phase-2/3 safety results confirming that profile; its Clinical trial design section identifies the presented data as coming from a phase-I/II trial. (LLM, conf=0.85)
plain- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Partly supported
Every source the paper cites for this claim was checked and supports it.
In the paper
“In addition, the reactogenicity profile of BNT162b2 represented mainly short-term local (i.e., injection site) and systemic responses.”
§ Safety and Efficacy of the BNT162b2 mRNA Covid-19 Vaccine > Abstract > Conclusions
What the sources say
- Supportedcites [8] Sahin U, Muik A, Vogler I, et al. BNT162b2 induces SARS-CoV-2-neutralising antibodies and T cells in humans. December 11, 2020 (https://www.medrxiv.org/content/10.1101/2020.12.09.20245175v1). preprint. source
The Safety and tolerability section reports local reactions, predominantly injection-site pain, and systemic reactions including fatigue and headache. It says reactions began within 24 hours and mostly resolved within two or three days, supporting the description of mainly short-term responses. (LLM, conf=0.94)
plain- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Supported
The cited sources that could be checked couldn’t confirm or dispute this claim.
In the paper
“Severe fatigue was observed in approximately 4% of BNT162b2 recipients, which is higher than that observed in recipients of some vaccines recommended for older adults.12”
§ Safety and Efficacy of the BNT162b2 mRNA Covid-19 Vaccine > Discussion
What the sources say
- Could not verifycites [12] Cowling BJ, Perera RAPM, Valkenburg SA, et al. Comparative immunogenicity of several enhanced influenza vaccine options for older adults: a randomized, controlled trial. Clin Infect Dis 2020; 71: 1704- 1714. 31828291 PMC7289658 sourceExperimental — accuracy not yet measured
The Results section reports local reactions and serious adverse events after influenza vaccination, but gives no rate of severe fatigue. Searches for severe fatigue and systemic reactions found no passage in our copy that supports the comparison with BNT162b2 recipients. (LLM, conf=0.72)
plain- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: unclear — It is unclear whether the paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Could not verify
Every source the paper cites for this claim was checked and supports it.
In the paper
“The cumulative incidence of Covid-19 cases over time among placebo and vaccine recipients begins to diverge by 12 days after the first dose, 7 days after the estimated median viral incubation period of 5 days,10 indicating the early onset of a partially protective effect of immunization.”
§ Safety and Efficacy of the BNT162b2 mRNA Covid-19 Vaccine > Discussion
What the sources say
- Supportedcites [10] Lauer SA, Grantz KH, Bi Q, et al. The incubation period of coronavirus disease 2019 (COVID-19) from publicly reported confirmed cases: estimation and application. Ann Intern Med 2020; 172: 577- 582. 32150748 PMC7081172 source
The Discussion reports a median incubation period of 5.2 days, supporting the approximately five-day estimate to which the citation is attached. The vaccine–placebo divergence is not attributed to this source. (LLM, conf=0.93)
plainstates an association- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Supported
A result the paper reports from its own data — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“No deaths were considered by the investigators to be related to the vaccine or placebo.”
§ Safety and Efficacy of the BNT162b2 mRNA Covid-19 Vaccine > Results > Adverse Events
plain- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
26 more claims
Create a free account to see all 69 claims and to verify the 1 reference still open.
- It may state two separate claims as one. 28
- Probably not a substantial claim. 12
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The cited source doesn’t support the claim as written.
In the citing paper
“This is notable, as these titers were associated with 95% protection from COVID-19 in phase 3 trials (44, 46, 48, 49).”
From mRNA vaccination boosts cross-variant neutralizing antibodies elicited by SARS-CoV-2 infection (2021) · cites this paper as [46]
Checked by a reasoning model — may be wrong.
Experimental — accuracy not yet measuredThe cited source doesn’t support the claim as written.
In the citing paper
“However, both the Oxford-AstraZeneca and Pfizer vaccines give substantial initial efficacy after a single dose of vaccine against parental strains (∼76 and 89%, respectively)”
From Evidence of escape of SARS-CoV-2 variant B.1.351 from natural and vaccine-induced sera (2021) · cites this paper as Polack et al., 2020
Checked by a reasoning model — may be wrong.
Experimental — accuracy not yet measuredThe cited source doesn’t support the claim as written.
In the citing paper
“Most large Covid-19 vaccine efficacy trials have reported notably increased vaccine efficacy against severe versus mild to moderate disease.4–7”
From Efficacy of NVX-CoV2373 Covid-19 Vaccine against the B.1.351 Variant (2021) · cites this paper as [5]
Checked by a reasoning model — may be wrong.
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“The majority of COVID-19 vaccines are designed to evoke humoral and cellular immune responses against the SARS-CoV-2 spike protein — responses that may not prevent infection but robustly protect against severe COVID-19, at least for certain periods of time11,150–157.”
From COVID-19 and cellular senescence (2023) · cites this paper as [11]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“The primary endpoints of the COVID-19 mRNA vaccine clinical trials were a non-severe infection with at least one clinical symptom [31,32].”
From Relative risk reduction: Misinformative measure in clinical trials and COVID-19 vaccine efficacy (2022) · cites this paper as [32]
Experimental — accuracy not yet measured
84 more claims about this paper
Create a free account to see every claim other papers make about this one.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
Each contradiction between two passages listed here was confirmed by an independent check.
Rated minor: it would not touch a result — a value no result rests on, a p-value that stays on the same side of the significance level, or a conflict that is clerical, resolved elsewhere in the paper, or outside its own findings.
In the paper
§ Safety and Efficacy of the BNT162b2 mRNA Covid-19 Vaccine > Results > Safety
“although fatigue and headache were also reported by many placebo recipients”
§ Safety and Efficacy of the BNT162b2 mRNA Covid-19 Vaccine > Results > Safety
“23% and 24%, respectively, after the second dose, among younger vaccine recipients; 17% and 14% among older recipients”
Citations
Cites
Cryo-EM structure of the 2019-nCoV spike in the prefusion conformation
Wrapp, D., Wang, N., Corbett, K. S., Goldsmith, J. A., Hsieh, C.-L., Abiona, O., Graham, B. S., & McLellan, J. S. (2020) · Science · doi:10.1126/science.abb2507 · Cited by 8,897
Lauer, S. A., Grantz, K. H., Bi, Q., Jones, F. K., Zheng, Q., Meredith, H. R., Azman, A. S., Reich, N. G., & Lessler, J. (2020) · Annals of Internal Medicine · doi:10.7326/m20-0504 · Cited by 5,970
RNA-Based COVID-19 Vaccine BNT162b2 Selected for a Pivotal Efficacy Study
Walsh, E. E., Frenck, R., Falsey, A. R., Kitchin, N., Absalon, J., Gurtman, A., Lockhart, S., Neuzil, K., Mulligan, M. J., Bailey, R., et al. (2020) · doi:10.1101/2020.08.17.20176651 · Cited by 2,615
Self-citationKarikó, K., Muramatsu, H., Welsh, F. A., Ludwig, J., Kato, H., Akira, S., & Weissman, D. (2008) · Molecular Therapy · doi:10.1038/mt.2008.200 · Cited by 1,930
Pardi, N., Tuyishime, S., Muramatsu, H., Kariko, K., Mui, B. L., Tam, Y. K., Madden, T. D., Hope, M. J., & Weissman, D. (2015) · Journal of Controlled Release · doi:10.1016/j.jconrel.2015.08.007 · Cited by 1,014
BNT162b2 vaccine induces neutralizing antibodies and poly-specific T cells in humans
Sahin, U., Muik, A., Vogler, I., Derhovanessian, E., Kranz, L. M., Vormehr, M., Quandt, J., Bidmon, N., Ulges, A., Baum, A., et al. (2021) · Nature · doi:10.1038/s41586-021-03653-6 · Cited by 919
Self-citationBNT162b2 induces SARS-CoV-2-neutralising antibodies and T cells in humans
Sahin, U., Muik, A., Vogler, I., Derhovanessian, E., Kranz, L. M., Vormehr, M., Quandt, J., Bidmon, N., Ulges, A., Baum, A., et al. (2020) · doi:10.1101/2020.12.09.20245175 · Cited by 914
Self-citationProspects for a safe COVID-19 vaccine
Haynes, B. F., Corey, L., Fernandes, P., Gilbert, P. B., Hotez, P. J., Rao, S., Santos, M. R., Schuitemaker, H., Watson, M., & Arvin, A. (2020) · Science Translational Medicine · doi:10.1126/scitranslmed.abe0948 · Cited by 261
Cowling, B. J., Perera, R. A. P. M., Valkenburg, S. A., Leung, N. H. L., Iuliano, A. D., Tam, Y. H., Wong, J. H. F., Fang, V. J., Li, A. P. Y., So, H. C., et al. (2020) · Clinical Infectious Diseases · doi:10.1093/cid/ciz1034 · Cited by 110
Cited by
Items 4,801–4,900 of 15,747
Humoral immunity and B-cell memory in response to SARS-CoV-2 infection and vaccination
Fryer, H. A., Hartley, G. E., Edwards, E. S. J., O’Hehir, R. E., & van Zelm, M. C. (2022) · Biochemical Society Transactions · doi:10.1042/bst20220415 · Cited by 19
(2021) · doi:10.1101/2021.06.25.21259544 · Cited by 20
“These frequencies paralleled those observed in the clinical trials of BNT162b2 (3, 4).”
BackgroundResultInfluentialSu, L.-J., Wang, N.-N., Luo, R.-S., Ji, Z.-H., Gu, H., Yang, C., Xu, M.-X., Zhang, J., Chen, Q., Yu, M., et al. (2026) · Nature Biomedical Engineering · doi:10.1038/s41551-026-01640-8 · Cited by 38
Preclinical immunogenicity and safety of hemagglutinin-encoding modRNA influenza vaccines
Hauguel, T., Sharma, A. M., Mastrocola, E., Lowry, S., Maddur, M. S., Hu, C. H., Rajput, S., Vitsky, A., Choudhary, S., Manickam, B., et al. (2024) · npj Vaccines · doi:10.1038/s41541-024-00980-3 · Cited by 23
COVID-19 vaccination strategies depend on the underlying network of social interactions
Herrmann, H. A., & Schwartz, J. (2021) · Scientific Reports · doi:10.1038/s41598-021-03167-1 · Cited by 23
Tissue immunity to SARS‐CoV‐2: Role in protection and immunopathology*
Rybkina, K., Davis‐Porada, J., & Färber, D. L. (2022) · Immunological Reviews · doi:10.1111/imr.13112 · Cited by 20
Poly(2-methyl-2-oxazoline) as a polyethylene glycol alternative for lipid nanoparticle formulation
van Zyl, D. G., Mendes, L. P., Semper, R. P., Rueckert, C., & Baumhof, P. (2024) · Frontiers in Drug Delivery · doi:10.3389/fddev.2024.1383038 · Cited by 25
SARS-CoV-2 vaccine-related neurological complications
Oonk, N. G. M., Ettema, A. R., van Berghem, H., de Klerk, J. J., van der Vegt, J. P. M., & van der Meulen, M. (2022) · Neurological Sciences · doi:10.1007/s10072-022-05898-z · Cited by 19
“First, headache is commonly seen in patients suffering from a respiratory virus and after a vaccination, including SARS-CoV-2-vaccines [3, 4].”
BackgroundMethodInfluentialDistinct Inflammatory Programs Underlie the Intramuscular Lipid Nanoparticle Response
Dowell, W. R., Dearborn, J. S., Languon, S., Miller, Z. D., Kirch, T., Paige, S., Garvin, O., Kjendal, L., Harby, E., Zuchowski, A. B., et al. (2024) · The Journal of Immunology · doi:10.1021/acsnano.4c08490 · Cited by 26
Clinical and Molecular Relationships between COVID-19 and Feline Infectious Peritonitis (FIP)
Sweet, A., André, N. M., Stout, A. E., Licitra, B. N., & Whittaker, G. R. (2022) · Viruses · doi:10.3390/v14030481 · Cited by 21
Al‐Obaydi, S., Hennrikus, E. F., Mohammad, N., Lehman, E. B., Thakur, A., & Al‐Shaikhly, T. (2022) · PLoS ONE · doi:10.1371/journal.pone.0272691 · Cited by 20
Wafula, S. T., Mugume, I. B., Sensasi, B., Okware, S., Chimbaru, A., Nanyunja, M., Talisuna, A. O., Kabanda, R., Bakyaita, T., Wanyenze, R. K., et al. (2022) · BMJ Open · doi:10.1136/bmjopen-2021-057322 · Cited by 19
Septic Arthritis of the Shoulder After SARS-CoV-2 Pfizer Vaccination
Massel, D. H., Haziza, S., Rivera, S., Mohile, N. V., Subhawong, T. K., & Hernandez, V. H. (2021) · JBJS Case Connector · doi:10.2106/jbjs.cc.21.00090 · Cited by 21
Stærke, N. B., Reekie, J., Johansen, I. S., Nielsen, H., Benfield, T., Wiese, L., Søgaard, O. S., Tolstrup, M., Iversen, K. K., Tarp, B., et al. (2022) · BMJ Open · doi:10.1136/bmjopen-2022-069065 · Cited by 21
Baltas, I., Boshier, F. A. T., Williams, C. A., Bayzid, N., Cotic, M., Guerra‐Assunção, J. A., Irish, D. N., Haque, T., Hart, J., Roy, S., et al. (2021) · Clinical Infectious Diseases · doi:10.1093/cid/ciab714 · Cited by 25
“Authorization trials were powered to detect differences in COVID-19 cases yet studied primarily young healthy adults[1-4].”
Ye, X., Yan, V. K. C., Yiu, H. H. E., Shami, J. J. P., Kang, W. C. M., Ma, T., Qin, X. S., Chui, C. S. L., Lai, F. T. T., Li, X., et al. (2023) · Journal of the American Heart Association · doi:10.1161/jaha.122.029291 · Cited by 21
Diagnostic performance of a novel antigen-capture ELISA for the detection of SARS-CoV-2
Yadegari, H., Mohammadi, M., Maghsood, F., Vanan, A. G., Bahadori, T., Golsaz‐Shirazi, F., Zarnani, A., Salimi, V., Jeddi‐Tehrani, M., Amiri, M. M., et al. (2023) · Analytical Biochemistry · doi:10.1016/j.ab.2023.115079 · Cited by 21
Survival and Incidence of COVID-19 After SARS-CoV-2 Vaccination in a Series of 2391 Cancer Patients
Heudel, P., Favier, B., Solodky, M.-L., Assaad, S., Chaumard, N., Trédan, O., Bachelot, T., Ray-Coquard, I. L., Russias, B., Fournier, M.-L., et al. (2021) · European Journal of Cancer · doi:10.1016/j.ejca.2022.01.035 · Cited by 20
Forgacs, D., Silva‐Moraes, V., Sautto, G. A., Hanley, H. B., Gattiker, J. L., Jefferson, A. M., Kolhe, R. B., & Ross, T. M. (2022) · Vaccines · doi:10.3390/vaccines10050696 · Cited by 22
“These vaccines are administered intramuscularly as two doses 21 or 28 days apart, respectively [5,6].”
BackgroundLi, K., Luo, R., Yu, X., Dong, W., Hao, G., Hu, D., Yu, Z., Liu, M., Lu, T., Wang, X., et al. (2025) · Clinical and Translational Medicine · doi:10.1002/ctm2.70250 · Cited by 23
“This technology has already found application in clinical prophylaxis, 12,13 and its application in regenerative medicine continues to evolve.”
COVID ‐19 mRNA vaccine‐related interstitial lung disease: Two case reports and literature review
So, C., Izumi, S., Ishida, A., Hirakawa, R., Kusaba, Y., Hashimoto, M., Ishii, S., Miyazaki, H., Iikura, M., & Hojo, M. (2022) · Respirology Case Reports · doi:10.1002/rcr2.938 · Cited by 19
“A two-dose regimen of BNT162b2 conferred 95% protection against COVID-19 in phase III clinical trials.(1) Furthermore, a series of reports has shown that the third dose of mRNA vaccines is effective against SARS-CoV-2 Omicron variant,(2,3) which will further increase the absolute number of vaccination opportunities.”
BackgroundmRNA medicine: Recent progresses in chemical modification, design, and engineering
Hou, X., Shi, J., & Xiao, Y. (2024) · Nano Research · doi:10.1007/s12274-024-6978-6 · Cited by 28
Challenges and opportunities in mRNA vaccine development against bacteria
Aernout, I., Verbeke, R., Théry, F., Willems, P. J., Elia, U., Smedt, S. C. D., Rappuoli, R., Peer, D., Impens, F., & Lentacker, I. (2025) · Nature Microbiology · doi:10.1038/s41564-025-02070-z · Cited by 25
“The fact that BioNTech is retesting the role of mRNA modifications in their Mtb candidates is also intriguing, given that m1Ψ-modified mRNA was chosen over unmodified mRNA and self-amplifying mRNA in the development of their COVID-19 mRNA vaccine 78 .”
Structural stability and RNase resistance of mRNA Polyplex micelles for systemic delivery
Dirisala, A., Uchida, S., Toh, K., Li, J., Liu, X., Wen, P., Fukushima, S., & Kataoka, K. (2025) · Journal of Controlled Release · doi:10.1016/j.jconrel.2025.113935 · Cited by 23
Assessment of COVID-19 vaccination among healthcare workers in Iraq; adverse effects and hesitancy
Darweesh, O., Khatab, N., Kheder, R. K., Mohammed, T., Faraj, T. A., Ali, S., Ameen, M., Kamal-Aldin, A., Alswes, M., & Al-Jomah, N. A. (2022) · PLoS ONE · doi:10.1371/journal.pone.0274526 · Cited by 19
“In line with our study, local injection site symptoms were the most common adverse effects in the Pfizer COVID-19 clinical trial [34].”
ResultNaveen, R., Parodis, I., Joshi, M. M., et al. (2022) · Lara D. Veeken · doi:10.1093/rheumatology/keac624 · Cited by 19
Axillary Lymphadenopathy After COVID-19 Vaccination in a Woman With Breast Cancer
Lam, D. L., & Flanagan, M. R. (2021) · JAMA · doi:10.1001/jama.2021.20010 · Cited by 19
A comparison of four epidemic waves of COVID-19 in Malawi; an observational cohort study
Anscombe, C., Lissauer, S., Thole, H., Rylance, J., Dula, D., Menyere, M., Kutambe, B. M., van der Veer, C., Phiri, T., Banda, N. P. K., et al. (2023) · BMC Infectious Diseases · doi:10.1186/s12879-022-07941-y · Cited by 27
“The early release of the Wuhan-1 genome sequence [4] enabled the development of specific diagnostic tests [5] and the design of mRNA vaccines, used to great success in high-income countries [6, 7].”
BackgroundSafety and Long-Term Immunogenicity of BNT162b2 Vaccine in Individuals with Down Syndrome
Valentini, D., Cotugno, N., Scoppola, V., Camillo, C. D., Colagrossi, L., Manno, E. C., Perno, C. F., Russo, C., Palma, P., Rossi, P., et al. (2022) · Journal of Clinical Medicine · doi:10.3390/jcm11030694 · Cited by 19
“In line with data from the general population [17], our data support a good safety profile for individuals with DS.”
ResultSARS-CoV-2–Specific Vaccine Candidates; the Contribution of Structural Vaccinology
Pack, S. M., & Peters, P. J. (2022) · Vaccines · doi:10.3390/vaccines10020236 · Cited by 20
“On the other hand, the Pfizer-BioNTech’s two-dose regimen of complete S protein vaccine initially achieved 95% protection against the original strain [54], however, it only offered 87% and 72.”
BackgroundMethodAdverse reactions to BNT162b2 mRNA COVID-19 vaccine in medical staff with a history of allergy
Inoue, S., Igarashi, A., Morikane, K., Hachiya, O., Watanabe, M., Kakehata, S., Sato, S., & Ueno, Y. (2021) · Respiratory Investigation · doi:10.1016/j.resinv.2021.11.007 · Cited by 20
“[1] Polack FP, Thomas SJ, Kitchin N, Absalon J, Gurtman A, Lockhart S, et al.”
BackgroundInfluentialCorrelation between COVID-19 and hepatitis B: A systematic review
He, Y., Jiang, Z., Ni, W., Bian, N., & Ren, J. T. (2022) · World Journal of Gastroenterology · doi:10.3748/wjg.v28.i46.6599 · Cited by 22
Sellner, J., Jenkins, T. M., von Oertzen, T. J., Bassetti, C. L., Beghi, E., Bereczki, D., Bodini, B., Cavallieri, F., Liberto, G. D., Helbok, R., et al. (2021) · European Journal of Neurology · doi:10.1111/ene.14741 · Cited by 19
Wolf, M. A., O’Hara, J. M., Bitzer, G. J., Narayanan, E., Boehm, D. T., Bevere, J. R., DeJong, M. A., Hall, J. M., Wong, T. Y., Falcone, S., et al. (2024) · npj Vaccines · doi:10.1038/s41541-024-00890-4 · Cited by 23
Cable News and COVID-19 Vaccine CompliancePreprint
Pinna, M., Picard, L., & Goessmann, C. (2021) · SSRN Electronic Journal · doi:10.2139/ssrn.3890340 · Cited by 19
The Effectiveness of COVID-19 Vaccines in Improving the Outcomes of Hospitalized COVID-19 Patients
Alsaffar, W. A., Alwesaibi, A. A., Alhaddad, M. J., Alsenan, Z. K., Alsheef, H. J., AlRamadan, S., Aljassas, H. A., Alsaghirat, M. A., & Alzahrani, H. J. (2022) · Cureus · doi:10.7759/cureus.21485 · Cited by 22
“6) in preventing symptomatic COVID-19 at or after day 7 following the second dose in placebo-controlled multinational trials [12].”
BackgroundInfluentialImmune Response and Safety of SARS-CoV-2 mRNA-1273 Vaccine in Patients With Myasthenia Gravis
Reyes‐Leiva, D., López-Contreras, J., Moga, E., et al. (2022) · Neurology Neuroimmunology & Neuroinflammation · doi:10.1212/nxi.0000000000200002 · Cited by 19
“RELATED ARTICLE Comment Humoral and T-cell Immunities toSARS-CoV-2 Vaccines: Safety, Efficacy, and Challenges in Autoimmune Neurology Page e200010 MORE ONLINE Class of Evidence Criteria for rating therapeutic and diagnostic studies NPub.org/coe COVID-19 Resources For the latest articles, invited commentaries, and blog…”
BackgroundInfluentialVacinação do Cardiopata contra COVID-19: As Razões da Prioridade
Martins, W. D. A., de Oliveira, G. M. M., Brandão, A. A., Mourilhe‐Rocha, R., Mesquita, E. T., Saraiva, J. F. K., Bacal, F., & Lopes, M. A. C. Q. (2021) · Arquivos Brasileiros de Cardiologia · doi:10.36660/abc.20210012 · Cited by 34
Adam, S. E., Zou, M., Kim, S., Henry, B., Krajden, M., & Skowronski, D. M. (2022) · Open Forum Infectious Diseases · doi:10.1093/ofid/ofac178 · Cited by 18
“Given analyses based upon testing rather than onset date, we incorporated additional lag time, in addition to the expected timeline for vaccine-induced immunity following each dose [8].”
Boff, M. O., Xavier, F. A. C., Diz, F. M., Gonçalves, J. B., Ferreira, L. O., Zambeli, J., Pazzin, D. B., Previato, T. T. R., Erwig, H. S., Gonçalves, J. I. B., et al. (2025) · Cells · doi:10.3390/cells14090662 · Cited by 25
“…medicine, facilitating the treatment of various diseases, including COVID-19, cancer, schizophrenia, and multiple sclerosis [163,168,172,176], and their ability to deliver molecular cargo, such as nucleoside-modified messenger RNA (modRNA), has shown considerable therapeutic potential [169].”
Trends in the synthetic polymer delivery of RNA
Friesen, J. J., & Blakney, A. K. (2024) · The Journal of Gene Medicine · doi:10.1002/jgm.3672 · Cited by 26
“6 However, these particles have several disadvantages, including limits on extrahepatic targeting and inherent immune stimulation.”
BackgroundSeparation of long-stranded RNAs by RP-HPLC using an octadecyl-based column with super-wide pores
Kuwayama, T., Ozaki, M., Shimotsuma, M., & Hirose, T. (2022) · Analytical Sciences · doi:10.1007/s44211-022-00253-w · Cited by 19
Adverse reactions and safety profile of the mRNA COVID-19 vaccines among Asian military personnel
Singapore Armed Forces, S., Tan, J. T., Tan, C. M., Singapore Armed Forces, S., Teoh, J. Y., Singapore Armed Forces, S., Wahab, M. T., Singapore Armed Forces, S., Tan, G. Z., Singapore Armed Forces, S., et al. (2021) · Annals of the Academy of Medicine Singapore · doi:10.47102/annals-acadmedsg.2021345 · Cited by 19
Wang, C., Pan, Q., Chen, S., Zhang, Y., Xu, X., Yan, X., Guo, J., Chen, X., Li, B., Ganzorig, C., et al. (2025) · Journal of the American Chemical Society · doi:10.1021/jacs.5c08376 · Cited by 25
Khaled, S. M., Petcu, C. G., Bader, L., et al. (2021) · SSRN Electronic Journal · doi:10.2139/ssrn.3790446 · Cited by 19
Nanomedicine to deliver biological macromolecules for treating COVID-19
Wilson, B., & Geetha, K. M. (2022) · Vaccine · doi:10.1016/j.vaccine.2022.05.068 · Cited by 20
“The BNT162b2 is a lipid nanoparticle formulated, mRNA vaccine that encodes the spike glycoprotein of SARS-CoV-2 [77].”
Development and evaluation of an inactivated coxsackievirus A16 vaccine in gerbils
Sun, Y., Xia, Y., Fang, X., Lu, H.-J., Mao, Z., Gao, M. Q., Pan, T., Yao, P., Wang, Z., & Zhu, H. (2022) · Emerging Microbes & Infections · doi:10.1080/22221751.2022.2093132 · Cited by 17
“Currently, mRNA vaccines have been widely used in humans since the outbreak of the COVID-19 pandemic [24].”
BackgroundHasegawa, N., Matsuoka, R., Ishikawa, N., et al. (2022) · Clinical Journal of Gastroenterology · doi:10.1007/s12328-022-01654-0 · Cited by 19
“Although the COVID-19 vaccine was effective and the number of infections in Japan rapidly decreased, severe adverse effects of the vaccine were reported in global phase III clinical trials [1].”
BackgroundOhtsuka, J., Imai, M., Fukumura, M., Maeda, M., Eguchi, A., Ono, R., Maemura, T., Ito, M., Yamayoshi, S., Kataoka, Y., et al. (2021) · iScience · doi:10.1016/j.isci.2021.103379 · Cited by 20
Vaccines for the Elderly and Vaccination Programs in Europe and the United States
Anastassopoulou, C. G., Ferous, S., Medić, S., Siafakas, N., Boufidou, F., Gioula, G., & Tsakris, A. (2024) · Vaccines · doi:10.3390/vaccines12060566 · Cited by 25
“These 5 individuals were also incidentally randomized on the placebo cohort and, therefore, did not receive the vaccine [174].”
BackgroundSafety of Simultaneous vs Sequential mRNA COVID-19 and Inactivated Influenza Vaccines
Walter, E. B., Schlaudecker, E. P., Talaat, K. R., Rountree, W., Broder, K. R., Duffy, J., Grohskopf, L. A., Poniewierski, M. S., Spreng, R. L., Staat, M. A., et al. (2024) · JAMA Network Open · doi:10.1001/jamanetworkopen.2024.43166 · Cited by 21
van den Ouweland, F., Charpentier, N., Türeci, Ö., Rizzi, R., Mensa, F., Lindemann, C., & Pather, S. (2024) · Human Vaccines & Immunotherapeutics · doi:10.1080/21645515.2024.2315659 · Cited by 27
“19,38 These findings were supported by further study in different world regions 31,35 and Phase II/III trials in children >6 months of age.”
BackgroundSelf-citationCaocci, G., Mulas, O., Mantovani, D., et al. (2021) · Annals of Hematology · doi:10.1007/s00277-021-04613-w · Cited by 19
Luczkowiak, J., Labiod, N., Rivas, G. A., Rolo, M., Lasala, F., Lora‐Tamayo, J., Mancheño‐Losa, M., Rial‐Crestelo, D., Pérez‐Rivilla, A., Folgueira, M. D., et al. (2021) · The Journal of Infectious Diseases · doi:10.1093/infdis/jiab634 · Cited by 17
“All participants were vaccinated in January–February 2021 with 2 doses of the Pfizer-BNT162b2 vaccine 21 days apart [4].”
Smith, M. F., Holland, S. C., Lee, M. B., Hu, J. C., Pham, N. C., Sullins, R. A., Holland, L. A., Mu, T., Thomas, A. W., Fitch, R., et al. (2023) · mBio · doi:10.1128/mbio.03101-22 · Cited by 19
Antibody and T cell responses to COVID-19 vaccination in patients receiving anticancer therapies
Rouhani, S. J., Yu, J., Olson, D. J., Zha, Y., Pezeshk, A., Cabanov, A., Pyzer, A. R., Trujillo, J., Derman, B. A., O’Donnell, P. H., et al. (2022) · Journal for ImmunoTherapy of Cancer · doi:10.1136/jitc-2022-004766 · Cited by 22
Fang, Y., Ma, B., Zhao, Z., Xuan, Z., Wang, Y., Huang, C., Zhang, M., Zhou, L., Feng, Y., Li, K., et al. (2025) · Journal of the American Chemical Society · doi:10.1021/jacs.5c07897 · Cited by 23
Current Trends in Messenger RNA Technology for Cancer Therapeutics
Afzal, A., Abbasi, M. H., Ahmad, S., Sheikh, N., & Khawar, M. B. (2025) · Biomaterials Research · doi:10.34133/bmr.0178 · Cited by 25
“[8] been instrumental in improving mRNA transfection into vehicle cells by enhancing its stability and enabling an efficient uptake and cytoplasmic transport [ 24 ].”
Idres, Y. M., Idris, A., & Gao, W. (2025) · Drug Delivery and Translational Research · doi:10.1007/s13346-025-01815-x · Cited by 28
“A testament to that, includes the role of LNPs in the development of several mRNA vaccines, such as Pfizer-BioNTech (BNT162b2) [ 10] and Mod-erna (mRNA-1273) [11].”
Ishio, T., Tsukamoto, S., Yokoyama, E., Izumiyama, K., Saito, M., Muraki, H., Kobayashi, M., Mori, A., Morioka, M., & Kondo, T. (2023) · Annals of Hematology · doi:10.1007/s00277-023-05204-7 · Cited by 22
Sugasawa, T., Nakano, T., Fujita, S.-I., Matsumoto, Y., Ishihara, G., Aoki, K., Yanazawa, K., Ono, S., Tamai, S., Manevich, L., et al. (2021) · Genes · doi:10.3390/genes12081249 · Cited by 23
“Recently, gene therapy technology has also been used to develop vaccines based on mRNA [9] or adenoviral vectors [10] against coronavirus disease 2019 (COVID-19) caused by severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2).”
Kow, C. S., Ramachandram, D. S., & Hasan, S. S. (2021) · Immunopharmacology and Immunotoxicology · doi:10.1080/08923973.2021.1993894 · Cited by 19
“Several vaccines against severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) have been developed and being utilized in mass vaccination campaigns [4,5], but the unequal distribution of the vaccines and emergence of variants had led to waves of COVID-19 cases still being observed in many countries [6].”
BackgroundAuster, O., Finkel, U., Dagan, N., Barda, N., Laufer, A., Balicer, R. D., & Ben‐Shachar, S. (2022) · JAMA Network Open · doi:10.1001/jamanetworkopen.2022.7657 · Cited by 18
Bernhauerová, V., Lisowski, B., Rezelj, V. V., & Vignuzzi, M. (2021) · Journal of Theoretical Biology · doi:10.1016/j.jtbi.2021.110895 · Cited by 24
D’Onofrio, L., Coraggio, L., Zurru, A., Carlone, A., Mignogna, C., Moretti, C., Maddaloni, E., & Buzzetti, R. (2021) · Diabetes Research and Clinical Practice · doi:10.1016/j.diabres.2021.109022 · Cited by 20
“The development of effective vaccines against the SarsCov2 has been greetedwith enthusiasm as a possible ultimate solution to overcome the pandemic [5].”
BackgroundInfluentialWoelfel, S., Dütschler, J., König, M., Graf, N., Oikonomou, V., Krieger, C., Truniger, S., Franke, A., Eckhold, A., Forsch, K., et al. (2022) · Alimentary Pharmacology & Therapeutics · doi:10.1111/apt.17264 · Cited by 20
Graves’ Disease Following SARS-CoV-2 Vaccination: A Systematic Review
Patrizio, A., Ferrari, S. M., Elia, G., Ragusa, F., Paparo, S. R., Mazzi, V., Antonelli, A., & Fallahi, P. (2022) · Vaccines · doi:10.3390/vaccines10091445 · Cited by 23
“In a short time, numerous sera have been released [3], including, for the first time, mRNA-technology-based vaccines (Pfizer-Biontech’s BNT162b2 and Moderna’s mRNA-1273) [4,5].”
BackgroundCheng, Y., Li, T., Zheng, Y., Xu, B., Bi, Y., Hu, Y., & Zhou, Y. (2022) · Human Vaccines & Immunotherapeutics · doi:10.1080/21645515.2022.2064134 · Cited by 23
Medina-Magües, L. G., Mühe, J., Jasny, E., Medina-Magües, E. S., Roth, N., Lopera-Madrid, J., Salas-Quinchucua, C., Knuese, C., Petsch, B., & Osorio, J. E. (2023) · npj Vaccines · doi:10.1038/s41541-023-00629-7 · Cited by 19
Virus-Like Particles Are Efficient Tools for Boosting mRNA-Induced Antibodies
Vogt, A. S., Jörg, L., Martina, B. E. E., Krenger, P. S., Chang, X., Zeltiņš, A., Vogel, M. T., Mohsen, M. O., & Bachmann, M. F. (2022) · Frontiers in Immunology · doi:10.3389/fimmu.2022.864718 · Cited by 20
Effect of Vaccination against SARS-CoV-2 on Long COVID-19: A Narrative Review
Tofarides, A. G., Christaki, E., Milionis, H. J., & Nikolopoulos, G. K. (2022) · Life · doi:10.3390/life12122057 · Cited by 23
Germinal centre-driven maturation of B cell response to SARS-CoV-2 vaccinationPreprint
Kim, W., Zhou, J. Q., Sturtz, A. J., Horvath, S. C., Schmitz, A. J., Lei, T., Kalaidina, E., Thapa, M., Alsoussi, W. B., Haile, A., et al. (2021) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2021.10.31.466651 · Cited by 18
Bianchi, J., Hirt, J., Vogt, M., & Vetsch, J. (2025) · Cochrane Evidence Synthesis and Methods · doi:10.1002/cesm.70033 · Cited by 19
Lee, V., Adham, M., Kridis, W. B., Bossi, P., Chen, M.-Y., Chitapanarux, I., Grégoire, V., Hao, S.-P., Ho, C., Ho, G., et al. (2022) · The Lancet Oncology · doi:10.1016/s1470-2045(22)00505-8 · Cited by 18
Determinants of COVID-19 vaccine-induced myocarditis
Rose, J., Hulscher, N., & McCullough, P. A. (2024) · Therapeutic Advances in Drug Safety · doi:10.1177/20420986241226566 · Cited by 27
Toda, M., Yoshifuji, A., Kikuchi, K., Koinuma, M., Komatsu, M., Fujii, K., Kato, A., Kikuchi, T., Nakazawa, A., & Ryuzaki, M. (2022) · Clinical and Experimental Nephrology · doi:10.1007/s10157-022-02188-y · Cited by 18
Kang, H. S., Kim, J. E., Yoo, J. R., et al. (2022) · Infection and Chemotherapy · doi:10.3947/ic.2021.0131 · Cited by 19
Risma, K. (2021) · Current Opinion in Pediatrics · doi:10.1097/mop.0000000000001077 · Cited by 21
Onyeaghala, A., Anyiam, A., Husaini, D. C., Onyeaghala, E., & Obi, E. (2023) · Scientific African · doi:10.1016/j.sciaf.2023.e01627 · Cited by 17
Zhang, R., Liu, D., Leung, K., Fan, Y., Lu, L., Chan, P.-C., To, K. K., Chen, H., Yuen, K., Chan, K., et al. (2022) · Vaccines · doi:10.3390/vaccines10010072 · Cited by 23
“BNT162b2, as the first mRNA vaccine approved by WHO, has shown high effectiveness and safety in clinical trials [1,2].”
BackgroundSweet Syndrome Following SARS-CoV2 Vaccination
Baffa, M. E., Maglie, R., Giovannozzi, N., et al. (2021) · Vaccines · doi:10.3390/vaccines9111212 · Cited by 19
“A phase III trial, including 43,548 participants, reported mild–moderate cutaneous reactions, mainly consisting of redness and swelling at the injection site [7].”
BackgroundImmunogenicity and Efficacy of Vaccination in People Living with Human Immunodeficiency Virus
Tortellini, E., Ngangue, Y. C. F., Dominelli, F., Guardiani, M., Falvino, C., Mengoni, F., Carraro, A., Marocco, R., Pasculli, P., Mastroianni, C. M., et al. (2023) · Viruses · doi:10.3390/v15091844 · Cited by 32
Vress, D. (2021) · Best Practice & Research Clinical Obstetrics & Gynaecology · doi:10.1016/j.bpobgyn.2021.03.009 · Cited by 19
Comparative COVID-19 Vaccine Effectiveness Over Time in Veterans
Mayr, F., Talisa, V. B., Shaikh, O. S., Omer, S. B., Butt, A. A., & Yende, S. P. (2022) · Open Forum Infectious Diseases · doi:10.1093/ofid/ofac311 · Cited by 16
“Of note, the average age of participants in the international randomized controlled trial and subsequent real-world studies for the BNT162b2 vaccine was ∼50 years, and the proportion of subjects with comorbidities was low or not known [2, 3, 13, 14].”
BackgroundFukihara, J., & Kondoh, Y. (2023) · Respiratory Investigation · doi:10.1016/j.resinv.2023.05.007 · Cited by 24
Zhang, P., Falcone, S., Tsybovsky, Y., Singh, M., Gopan, V., Miao, H., Seo, Y., Rogers, D., Renzi, I., Lai, Y., et al. (2023) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.2305896120 · Cited by 21
“…the less- than-optimal breadth of neutralization and limited durability of protection against VOCs conferred by approved vaccines, despite a retained efficacy against severe disease (3, 8), make further improvements important for the global control and, ultimately, termination of the pandemic.”
COVID-19 Vaccines in Patients with Maintenance Hemodialysis
Yen, C.-C., Lin, S., Chen, S., Chiu, Y., Chang, J., & Hwang, S. (2021) · Journal of Personalized Medicine · doi:10.3390/jpm11080789 · Cited by 17
“It has completed a Phase 2/3 trial of 43,448 participants aged over 16 years and revealed an efficacy of 95% in preventing COVID-19 7 days after vaccination [22].”
BackgroundBaseline immune states (BIS) associated with vaccine responsiveness and factors that shape the BIS
Nehar-Belaid, D., Sokolowski, M. J., Ravichandran, S., Banchereau, J., Chaussabel, D., & Ucar, D. (2023) · Seminars in Immunology · doi:10.1016/j.smim.2023.101842 · Cited by 20
Ma, S., Zhu, F., Zhang, P., Xu, Y., Zhou, Z., Yang, H., Tan, C., Chen, J., & Pan, P. (2025) · Scientific Reports · doi:10.1038/s41598-024-84823-0 · Cited by 20
“Moreover, mRNA vaccines have shown notable advantages in combating COVID-19, including versatile antigen design, straightforward preparation procedures, and the capacity for rapid production scaling 30 .”
Yu, X., Liu, S., Cheng, Q., Lee, S. M., Wei, T., Zhang, D., Farbiak, L., Johnson, L. T., Wang, X., & Siegwart, D. J. (2021) · Pharmaceutics · doi:10.3390/pharmaceutics13111914 · Cited by 21
“The recent success of mRNA lipid nanoparticle (LNP) vaccines for SARS-CoV-2 has solidified the significant impact of this life-saving approach [15,16].”
BackgroundVargas, L., Valdivieso, N., Tempio, F., Simon, V., Sauma, D., Valenzuela-Pérez, L., Beltrán, C. J., Castillo-Delgado, L., Contreras-Benavides, X., Acevedo, M. L., et al. (2022) · BMC Medicine · doi:10.1186/s12916-022-02406-0 · Cited by 20
“In this study, only individuals who experienced COVID-19 symptoms were tested by PCR to confirm prior SARS-CoV2 infection (10 participants from group 1 out of 349 participants).”
InfluentialTherapeutic gene silencing of CKAP5 leads to lethality in genetically unstable cancer cells
Chatterjee, S., Naidu, G. S., Hazan‐Halevy, I., Grobe, H., Ezra, A., Sharma, P., Goldsmith, M., Ramishetti, S., Sprinzak, D., Zaidel‐Bar, R., et al. (2023) · Science Advances · doi:10.1126/sciadv.ade4800 · Cited by 23
Baldolli, A., Michon, J., Appia, F., Galimard, C., Verdon, R., & Parienti, J. (2021) · Vaccine · doi:10.1016/j.vaccine.2021.06.054 · Cited by 19
“This could be due to an older age as previous report showed poorer tolerance of mRNA vaccines in younger subjects.[4,5] On the 11th of March 2021, 5.”
BackgroundResultInfluentialChernyshev, M., Sakharkar, M., Connor, R. I., Dugan, H. L., Sheward, D. J., Rappazzo, C. G., Stålmarck, A., Forsell, M. N. E., Wright, P. F., Corcoran, M., et al. (2023) · Nature Communications · doi:10.1038/s41467-023-37972-1 · Cited by 17
Metadata
- Authors
- Polack, F. P., Thomas, S. J., Kitchin, N., Absalon, J., Gurtman, A., Lockhart, S., Perez, J. L., Pérez Marc, G., Moreira, E. D., Zerbini, C., Bailey, R., Swanson, K. A., Roychoudhury, S., Koury, K., Li, P., Kalina, W. V., Cooper, D., Frenck, R. W., Hammitt, L. L., Türeci, Ö., Nell, H., Schaefer, A., Ünal, S., Tresnan, D. B., Mather, S., Dormitzer, P. R., Şahin, U., Jansen, K. U., & Gruber, W. C.
- Affiliations
- Cincinnati Children's Hospital Medical Center (US)
- From Fundacion INFANT (F.P.P.) and iTrials-Hospital Militar Central (G.P.M.), Buenos Aires; State University of New York, Upstate Medical University, Syracuse (S.J.T.), and Vaccine Research and Development, Pfizer, Pearl River (J.A., A.G., K.A.S., K.K., W.V.K., D.C., P.R.D., K.U.J., W.C.G.) — both in New York; Vaccine Research and Development, Pfizer, Hurley, United Kingdom (N.K., S.L., R.B.); Vaccine Research and Development (J.L.P., P.L.) and Worldwide Safety, Safety Surveillance and Risk Management (S.M.), Pfizer, Collegeville, PA; Associação Obras Sociais Irmã Dulce and Oswaldo Cruz Foundation, Bahia (E.D.M.), and Centro Paulista de Investigação Clinica, São Paulo (C.Z.) — both in Brazil; Global Product Development, Pfizer, Peapack, NJ (S.R.); Cincinnati Children’s Hospital, Cincinnati (R.W.F.); Johns Hopkins Bloomberg School of Public Health, Baltimore (L.L.H.); BioNTech, Mainz (ÖT., U.Ş.), and Medizentrum Essen Borbeck, Essen (A.S.) — both in Germany; Tiervlei Trial Centre, Karl Bremer Hospital, Cape...
- Corresponding author
- Absalon, Judith
- ORCID
- Polack, Fernando P.
- Thomas, Stephen J.
- Kitchin, Nicholas
- Absalon, Judith
- Gurtman, Alejandra
- Lockhart, Stephen
- Moreira, Edson D.
- Zerbini, Cristiano
- Swanson, Kena A.
- Roychoudhury, Satrajit
- Li, Ping
- Cooper, David
- Frenck, Robert W.
- Hammitt, Laura L.
- Türeci, Özlem
- Ünal, Serhat
- Mather, Susan
- Dormitzer, Philip R.
- Şahin, Uğur
- Jansen, Kathrin U.
- Gruber, William C.
- Venue
- New England Journal of Medicine
- Publisher
- Massachusetts Medical Society
- Published
- 2020-12-31
- Volume
- 383
- Issue
- 27
- Pages
- 2603-2615
- ISSN
- 0028-4793 (ISSN-L)
- 1533-4406
- PMC
- PMC7745181
- OpenAlex
- W3111255098
- Cited by
- 14,592
- References
- 8
- Citations by year
- 2026: 756 · 2025: 1216 · 2024: 1543 · 2023: 2310 · 2022: 4192 · 2021: 4494 · 2020: 77
- FWCI
- 362.87
- Type
- journal article
- Language
- en
- Open access
- green
- www.ncbi.nlm.nih.gov
- Locations
- New England Journal of Medicine (publishedVersion)
- PubMed Central (publishedVersion)
- PubMed (publishedVersion)
- Arca - Repositório Institucional da Fiocruz (submittedVersion, other-oa)
- Repositorio Académico UPC (Universidad Peruana de Ciencias Aplicadas) (submittedVersion, cc-by-nc-nd)
- LA Referencia (Red Federada de Repositorios Institucionales de Publicaciones Científicas) (submittedVersion, other-oa)
- Funders
- BioNTech and Pfizer
- Topics
- Health Sciences › Medicine › Infectious Diseases › SARS-CoV-2 and COVID-19 Research
- Health Sciences › Medicine › Infectious Diseases › COVID-19 Clinical Research Studies
- Social Sciences › Health › Vaccine Coverage and Hesitancy
- Keywords
- BNT162b2, COVID-19 vaccines, SARS-CoV-2, mRNA vaccines, lipid nanoparticle formulation, vaccine efficacy, vaccine safety, severe COVID-19 prevention, two-dose regimen, serious adverse events, subgroup analysis, immunogenicity, immunocompromised patients, pregnant and lactating women
- MeSH terms
- COVID-19, SARS-CoV-2, COVID-19 Vaccines, mRNA Vaccines, BNT162 Vaccine, Adolescent, Adult, Aged, Fatigue, Female, Headache, Humans, Immunization, Secondary, Male, Middle Aged, Vaccines, Synthetic, Single-Blind Method, Treatment Outcome, Young Adult
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
The claim verdicts this report counts are experimental: their accuracy is not yet measured.
A language model drew the claims from the paper on 2026-10-10, under version 3 of the claim definition (model deepseek-v4.1-flash, prompt extract-v3).
A second model labelled each claim on 2026-10-10 (model jev-1.13-20260917, definition revision gold-guideline-v0.2).
Cited sources are checked with a language model’s help (gpt-6-sol).
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.